AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
8 reports, 3 independent
Updated Sep 8
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 8
- Developments
- 4
- Repetition
- 62%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.AbbVie and Genmab's joint development of a lymphoma drug has failed clinical trials.1 source
Successful Phase 3 trials for lymphoma and product efficacy gained for acute migraine.1 source
- A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.Sub-event
AbbVie and Genmab plan to engage global regulatory authorities.1 source
Keep exploring
The entities involved
Related events
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- AbbVie and Novo Nordisk are high-profile pharmaceutical stocks serving over 45 million people worldwide, with Cor acting as a significant distribution partner.
- AbbVie and Cisco are noted as large-cap holdings in the market.
- Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.
- Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.